Abstract: The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present invention provides hyaluronic acid derivatives into which a certain cationic group and a certain hydrophobic group are introduced, the hyaluronic acid derivatives including one or more repeating units represented by the formula (Ia) and one or more repeating units represented by the formula (Ib).

Abstract: A liquid crystal display (LCD) device and a method for driving LCD. Such a device may have a plurality of LCD pixels in a matrix, a driver that inputs a drive signal to each pixel selectively and a controller that controls a level and a polarity of the drive signal, and a memory storing corrected charge voltage values. Each pixel is provided with the drive signal based on the corrected charge voltage values for the corresponding pixel during the entirety of a horizontal period, and the corrected charge voltage value has a predetermined value corresponding to a charge for an intended gray scale level of the pixel at the end of the horizontal period without an over shooting of the driving voltage. When the target gray scale of the pixels is at the brightest level, a predetermined negative corrected charge is applied to the pixel to avoid an after image.

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: A radio communication control device accepts a call-up from a radio communication terminal and includes a unit configured to detect the degree of jamming in a cell, a unit configured to confirm the intention of a user of a terminal concerned as to whether the call-up is continued regardless of addition of an extra to the user's telephone call charge when the call-up has been made from a radio communication terminal in the cell concerned in a specific jammed state, a unit configured to block the call-up concerned in accordance with the confirmed intention of the user of the terminal concerned and a unit configured to change charge setting so as to add an extra to the user's telephone call charge when the call-up has not been blocked in the specific jammed state.

Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Abstract: A liquid crystal display (LCD) device and a method for driving LCD. Such a device may have a plurality of LCD pixels in a matrix, a driver that inputs a drive signal to each pixel selectively and a controller that controls a level and a polarity of the drive signal, and a memory storing corrected charge voltage values. Each pixel is provided with the drive signal based on the corrected charge voltage values for the corresponding pixel during the entirety of a horizontal period, and the corrected charge voltage value has a predetermined value corresponding to a charge for an intended gray scale level of the pixel at the end of the horizontal period without an over shooting of the driving voltage. When the target gray scale of the pixels is at the brightest level, a predetermined negative corrected charge is applied to the pixel to avoid an after image.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, JB, n, JD, J, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.

Abstract: A display device comprises: control circuit substrates disposed in a rear surface of a display panel, a control circuit that generates a control signal in order to control a data line driving circuit and a gate line driving circuit; gate connecting wirings; and a substrate connecting wiring, wherein each of the control circuit substrates includes: a first-side gate connecting part disposed on a first side; and a second-side substrate connecting part disposed on a second side, and the first-side gate connecting part and the second-side substrate connecting part are disposed so as not to overlap each other when the control circuit substrate is viewed in the first direction from the first side toward the second side.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Abstract: Provided is a raw material powder for powder metallurgy, capable of preventing stains, surface defects and decarburization of a sintered body, improving strength and density thereof. The raw material powder for powder metallurgy is for use in the production of a sintered body that is sintered at a temperature of not lower than 500° C., composed of a mixture of a metal powder and a lubricant, in which the lubricant is melamine cyanurate or terephthalic acid. Alternatively, the raw material powder for powder metallurgy is for use in the production of a sintered body that is sintered at a temperature of not lower than 500° C, composed of a mixture of a metal powder, a first lubricant and a second lubricant, in which the first lubricant is melamine cyanurate or terephthalic acid, while the second lubricant is preferably erucic acid amide or stearic acid amide.